Home » Stocks » AMGN

Amgen Inc. (AMGN)

Stock Price: $247.72 USD 2.98 (1.22%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $247.89 +0.17 (0.07%) Jul 23, 7:07 PM
Market Cap 142.33B
Revenue (ttm) 25.16B
Net Income (ttm) 7.09B
Shares Out 577.00M
EPS (ttm) 12.07
PE Ratio 20.52
Forward PE 15.06
Dividend $6.56
Dividend Yield 2.65%
Trading Day July 23
Last Price $247.72
Previous Close $244.74
Change ($) 2.98
Change (%) 1.22%
Day's Open 246.27
Day's Range 244.87 - 248.57
Day's Volume 1,747,301
52-Week Range 205.87 - 272.73


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Other stocks mentioned: ABBV, BMY, FHLC, GILD, IYH, JNJ, MRK ...
2 days ago - Zacks Investment Research

The FDA has issued an untitled letter to Amgen Inc (NASDAQ:AMGN) for the misbranding of its blockbuster bone marrow stimulant, Neulasta (pegfilgrastim) injection. Amgen released a promotional communicat...

1 week ago - Benzinga

THOUSAND OAKS, Calif., July 14, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN), in partnership with the International Federation of Psoriasis Associations (IFPA), announced the launch of the Understanding Pso...

1 week ago - PRNewsWire

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The approval covers Kyprolis in combination...

Other stocks mentioned: BGNE
2 weeks ago - Benzinga

The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.

Other stocks mentioned: AZN
2 weeks ago - Zacks Investment Research

The FDA has accepted for review Amgen Inc's (NASDAQ: AMGN) marketing application seeking approval for tezepelumab to treat asthma.  Amgen is developing Tezepelumab in collaboration with AstraZeneca plc ...

Other stocks mentioned: AZN
2 weeks ago - Benzinga

THOUSAND OAKS, Calif., July 7, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Pr...

2 weeks ago - PRNewsWire

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Other stocks mentioned: BIIB, BNTX, MRNA, NTLA, REGN, RGEN
2 weeks ago - Zacks Investment Research

Amgen has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $20.37B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.83% yield

2 weeks ago - Forbes

We have been long-term owners of Amgen ( AMGN , Financial), Merck ( MRK , Financial) and Pfizer ( PFE , Financial) among the major pharma and biotech companies. We believe they trade at a ridiculous dis...

Other stocks mentioned: LLY, MRK, PFE
3 weeks ago - GuruFocus

Amgen Inc (NASDAQ: AMGN) plans to build a $365 million pharmaceutical packaging facility in New Albany that will employ 400 workers.  The Ohio Tax Credit Authority Monday approved a state tax credit for...

3 weeks ago - Benzinga

Dear Fellow Shareholders,

Other stocks mentioned: AAPL, AMZN, AZN, BIIB, LLY, MSFT
3 weeks ago - GuruFocus

The ratio of return on invested capital (ROIC) compared to weighted average cost of capital (WACC) is an excellent way to determine which companies are best at maintaining and growing their profitabilit...

Other stocks mentioned: CL, SBUX, TROW
1 month ago - GuruFocus

THOUSAND OAKS, Calif., June 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab) f...

1 month ago - PRNewsWire

REYKJAVIK, Iceland, June 18, 2021 /PRNewswire/ -- Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts  the time to all-cause  death be...

1 month ago - PRNewsWire

Both of these companies raised their dividend payouts even amid the pandemic.

Other stocks mentioned: ABBV
1 month ago - The Motley Fool

Biotech stocks are rallying this month; can the trend continue?

Other stocks mentioned: BIIB, CLOV, GILD, IBB, INO, MRNA, XBI
1 month ago - Zacks Investment Research

THOUSAND OAKS, Calif., June 15, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign t...

1 month ago - PRNewsWire

Amgen Inc (NASDAQ: AMGN) presented data on overall survival from the Phase 2 results of the CodeBreaK 100 clinical study for Lumakras (sotorasib) in previously treated non-small-cell lung cancer (NSCLC)...

1 month ago - Benzinga

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m.

1 month ago - PRNewsWire

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for ...

1 month ago - PRNewsWire

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial.

1 month ago - PRNewsWire

The stock price of Amgen (NASDAQ: AMGN) has seen a 5% drop over the last five trading days. The decline can be attributed to profit taking before the U.S. FDA ruled out its verdict on the company's lung...

1 month ago - Forbes

The speedy approval of Lumakras could drive growth for years to come.

1 month ago - The Motley Fool

THOUSAND OAKS, Calif., June 1, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual...

1 month ago - PRNewsWire

Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

1 month ago - Zacks Investment Research

Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in developmen...

1 month ago - Benzinga

Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Sev...

1 month ago - PRNewsWire

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

1 month ago - Zacks Investment Research

Nano-X is not a safe investment -- it's a highly risky one. But its potential upside is incredible.

Other stocks mentioned: FUJIY, GE, GILD, NNOX, PHG, SIEGY, SKM
1 month ago - The Motley Fool

THOUSAND OAKS, Calif., May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m.

1 month ago - PRNewsWire

The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation. The approval covers the treatment of ad...

1 month ago - Benzinga

THOUSAND OAKS, Calif., May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult pa...

1 month ago - PRNewsWire

Matrix Asset's David Katz makes the case for Amgen, Viacom and Verizon

YouTube video

David Katz, Matrix Asset Advisors chief investment officer, and Jerry Castellini, CastleArk Management chief investment officer, join 'The Exchange' to discuss their market outlook as the economy reopen...

Other stocks mentioned: VIAC, VZ, VZA, BDX, BDXA
1 month ago - CNBC Television

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

When you have to grow your own nest egg, a balance among growth, reliability, and longevity must be found.

Other stocks mentioned: AAPL, PYPL
1 month ago - The Motley Fool

You won't be paying much of a premium for either of these dividend stocks.

Other stocks mentioned: CSCO
1 month ago - The Motley Fool

Excess free cash flow can often be used to generate long-term value for companies. Here are 10 FCF stocks that could be poised for growth.

Other stocks mentioned: AAPL, ACN, BBY, HCA, JPM, LEN, NUE ...
2 months ago - Kiplinger

Here's why you should consider buying into these two companies for the long run.

Other stocks mentioned: ABBV
2 months ago - The Motley Fool

THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m.

2 months ago - PRNewsWire

THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 Ameri...

2 months ago - PRNewsWire

I'm reiterating three Long Ideas that have underperformed the S&P 500 since my original reports: Amgen, Inc (AMGN), McDonald's Corporation (MCD), and Colgate-Palmolive Company (CL).

Other stocks mentioned: CL, MCD
2 months ago - Forbes

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz...

Other stocks mentioned: NVS
2 months ago - Benzinga

THOUSAND OAKS, Calif., May 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR...

2 months ago - PRNewsWire

THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) op...

2 months ago - PRNewsWire

THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Adm...

Other stocks mentioned: AZN
2 months ago - PRNewsWire

Everyone wants to be a contrarian investor. But in practice, most people buy more near tops and sell shares low.

Other stocks mentioned: ALB, GDV, XLF
2 months ago - Forbes

THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m.

2 months ago - PRNewsWire

THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sND...

2 months ago - PRNewsWire

There are certainly some problem spots for the big biotech.

2 months ago - The Motley Fool

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of... [Read more...]

Drug Manufacturers-General
Robert Bradway
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, Amgen's revenue was $25.42 billion, an increase of 8.83% compared to the previous year's $23.36 billion. Earnings were $7.26 billion, a decrease of -7.37%.

Financial Statements

Analyst Forecasts

According to 30 analysts, the average rating for Amgen stock is "Buy." The 12-month stock price forecast is 254.96, which is an increase of 2.92% from the latest price.

Price Target
(2.92% upside)
Analyst Consensus: Buy